Cervical neoplasia is the abnormal growth of cells on the surface of the cervix that could potentially lead to cervical cancer. Our work translates into developing and testing novel therapeutics aiming to eradicate persistent human papillomaviruses (HPV) infections in women with established pre-cancerous lesions in clinical trials. This has recently led to the first in-human trial of the world’s broadest HPV vaccine – and is a major milestone in the fight against HPV associated cancers.
Worldwide over 530,000 women are diagnosed with cervical cancer each year.
This is estimated to increase by approximately 2% per annum to 770,000 new cases by 2030.
Cervical cancer is the most common cancer in women under 35.
WHAT IS HPV?
First woman in UK receives dose of therapeutic HPV vaccine
5 July 2021
NDWRH and Vaccitech Ltd, a clinical-stage biopharmaceutical company engaged in the discovery and development of vaccines for the treatment and prevention of infectious diseases and cancer, see the first woman in the UK receive the first dose of a novel therapeutic HPV vaccine for the HPV001 clinical trial in Oxford.
Broadest ever therapeutic HPV vaccine to be tested in clinical trial. Treatment could clear up persistent infections and reduce risk of cervical cancer. Read Guardian article here
A multi-genotype therapeutic human papillomavirus vaccine elicits potent T cell responses to conserved regions of early proteins
DORRELL L. et al, (2019), Scientific Reports
Zheng Y. et al, (2018), Nature Communications, 9
Peripheral Basophil Count is Increased in Patients with Endometriosis.
Feng Q. et al, (2018), REPRODUCTIVE SCIENCES, 25, 218A - 218A
Hancock G. et al, (2018), Best Practice & Research Clinical Obstetrics & Gynaecology, 47, 59 - 72